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(EQ-5D and the condition speciﬁ c Dermatitis-Life-Quality-Index (DLQI)), direct and 
indirect costs, from the societal perspective. RESULTS: A preliminary sample of 305 
patients (mean age + SD = 41.4 + 14.9, 38.2% male) were enrolled. Two hundred 
ﬁ fty ﬁ ve patients (83.6%) had CHE and of these the 27.8% were severe. Overall, 
20.0% of the enrolled patients were chronic, severe and refractory to therapy. DLQI 
mean + SD sum score was 10.38 + 5.98. With EQ-5D 92.7% of patients reported 
moderate or severe pain/discomfort, 70.9% problems with usual activities, 58.2% 
anxiety/depression and 40% problems with self-care. VAS mean + SD = 61.96 + 21.48. 
On average hospitalization cost c87.90/patient-month, travels due to CHE cost 
c69.54/patient-month, specialist visit costs c52.81/patient-month, other products 
(gloves, gauze bandage, vacuum cleaner, cosmetics) costs c35.70/patient-month, diag-
nostic exam costs c20.77/patient-month, non pharmacological therapy (emollients, 
galenic products, soap, UV-ray) cost c15.65/patient-month and pharmacological 
therapy cost c9.22/patient-month. Patients lost a mean + SD 4.35 + 8.68 workdays/
patient-month for reasons attributable to their condition. CONCLUSIONS: most of 
the patients in the Italian centers of dermatology have CHE and a ﬁ fth are severe and 
refractory to therapy. Patients with severe CHE and refractoriness to therapy have 
poor HRQoL and high costs. a correct diagnosis and treatment is necessary to efﬁ -
ciently manage this condition.
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OBJECTIVES: It is assumed broadly that the costs caused by chronic hand eczema 
(CHE) are signiﬁ cant. However, there is a lack of cost-of-illness studies on CHE. The 
objective of this study is, therefore, to determine the direct and indirect costs of chronic 
hand eczema under routine conditions overall and in different treatment stages in 
Germany. METHODS: The survey was conducted in 24 outpatient practices and 
clinics across Germany. Patients with CHE refractory to potent topical treatments and 
insured by statutory health insurances were eligible. Patient characteristics and 
resource use were directly gathered from patients and physicians. Costs were evaluated 
from the societal perspective. Four treatment stages were deﬁ ned: only topical treat-
ments (stage I), additionally photo therapy (II), systemic therapy (III) and inpatient 
treatment (IV). Bivariate associations between costs and treatment stage were assessed. 
RESULTS: A total of 223 CHE patients enrolled in the study. The yearly direct and 
indirect costs per patient are c1742 (SE: c139) and c386 (c83), respectively. a total 
of 63.2% of patients were treated only with topical treatments; additionally 15.7% 
with photo therapy, 11.7% with systemic treatments. a total 9.4% of all patients were 
admitted to hospitals. The total costs increase with treatment stage I-IV (P < 0.001): 
c1044 (c85), c2307 (c145), c2697 (c461) and c8407 (c991), respectively. Accord-
ingly, costs also correlated with clinical severity. CONCLUSIONS: CHE patients 
refractory to topical steroids incur marked costs to the society. The costs are increasing 
disproportionately with escalating treatment stages, especially in patients admitted to 
hospitals. Hence, new and innovative treatments may help to reduce the societal costs 
of CHE.
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OBJECTIVES: The objective of this analysis was to estimate the total budget dedicated 
to glaucoma care according to the UKGPRD and to identify factors associated with 
high costs. METHODS: Data were extracted on patients treated on the National 
Health Service with a diagnosis of ocular hypertension or glaucoma, or treated with 
topical intraocular lowering treatment, surgery or laser for glaucoma. The budget was 
estimated from resources consumed in 2008 and included glaucoma drugs, laser, 
surgery, hospitalization, specialist and general practitioner (GP) visits. In-patient 
resources were estimated from the Hospital Episode Statistics. Results were expressed 
in GBP, 2008. Factors associated with high cost were identiﬁ ed using linear stepwise 
regression. National extrapolation was performed according to the relative size of the 
GPRD to the UK general populations. RESULTS: Details of 33,441 patients were 
extracted, which suggests that about 510,000 patients were treated in the NHS in UK 
in 2008. The Mean age was 74.2 years, and 47.3% were male. The initial diagnosis 
was made at 67.8 years. Older patients, longer time since diagnosis, a higher number 
of previous treatments, a higher number of treatment switches in the previous one 
year period and use of laser/surgery were associated with a higher annual cost. Spend-
ing varied little between regions. Annual drug spending was £91.2 million on in-
patient care, £4.4 million on drug prescription renewal (not speciﬁ c to the glaucoma 
drug). Visits to the GP cost £34.8 million and visits to the eye specialist was >£54.0 
million although the latter ﬁ gure is likely to be an under estimate (GPRD underre-
ported eye doctor care). CONCLUSIONS: The 2008 expenditures to care for glau-
coma were >£185 million with no regional differences. Three factors were strongly 
associated with high costs: time since diagnosis, treatment changes, and rescue treat-
ment. This analysis suggests that longer treatment persistence is likely to be associated 
with cost saving.
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OBJECTIVES: Published cost-of-illness studies of psoriasis in Sweden are not avail-
able. This study estimates the societal cost of psoriasis care in a deﬁ ned Swedish patient 
population. METHODS: A prevalence-based prospective recruitment of patients visit-
ing two dermatology clinics in Sweden between September and December 2009 was 
performed. Patients collected resource utilization of health care contacts, treatment, 
travelling distance and time, and productivity loss (human capital approach) during 
1 month (Swedish unit prices, 2009). RESULTS: A total of 164 patients (49% males) 
were included; average age 52, 76% plaque psoriasis with PASI 5.7, DLQI 7.7 and 
EQ-5D utility weight 0.71. The mean total cost per patient-month was c994. Main 
cost drivers were outpatient visits (OP) and light therapy (49%), biological drugs 
(20%) and productivity loss (22%). When patients were stratiﬁ ed according to treat-
ment strategy, total costs (fraction of patients) for topical treatment only (TT; 34%) 
was c369, light therapy (LT; 24%) c1274, traditional systemic treatment (TST; 26%) 
c1085 and biological systemic treatment (BST; 16%) c1709 per patient-month. Main 
cost drivers in each treatment strategy were: OP (56%) in TT, OP (78%) in LT, 
productivity loss (40%) in TST and biological drugs (71%) in BST. There was no 
clear relationship between clinical (PASI) or subjective (DLQI) severity estimations 
and costs. CONCLUSIONS: In this study the cost-of-illness for a psoriasis patient 
amounts to almost c1000/month, with great variation depending on treatment strat-
egy. Despite the 1200 difference in drug cost for TST vs. BST, total cost per month 
differed by c600 because of offsets from improved productivity and reductions in OP 
and topical treatment. As expected, biologically treated patients had higher costs but 
lower severity probably due to the treatment effectiveness. The relationship between 
costs and severity is complex, probably due to the selected study period and differences 
in effect between strategies.
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OBJECTIVES: Wet macular degeneration associated with age (wet-AMD) is the 
leading cause of legal blindness in Spain in people over 55. The aim of this study is 
to determine health care resource utilization and mean costs per patient with wet-AMD 
in 2009. METHODS: A micro-costing analyses was performed to estimate direct 
medical costs of patients with wet-AMD. Patient level data was obtained from differ-
ent public hospitals in Spain and ophthalmologists were surveyed with a semi-struc-
tured questionnaire to obtain treatment patterns. Inpatient costs were considered from 
the perspective of the public health care system. Treatments under study were pegap-
tanib, verteporﬁ n, ramibizumab and bavacizumab. Although bevacizumab in Spain is 
not approved for wet-AMD, it was used off-label in the hospital. Direct medical costs 
considered were drug costs, administration cost, doctors’ visits, nurse time, ophthal-
mologist time, anaesthetics, ambulant hospital care, external consultation, surgery and 
treatment of adverse effects. All costs are referred to 2009. RESULTS: Mean cost per 
patient treated with wet-AMD represented the following cost for the public health 
care system: c7290 for pegaptanib, c5810c for verteporﬁ n, c8650 for ramibizumab 
and c3110 for bevacizumab. We also estimated that in Spain 180,000 people over 50 
years have wet-AMD in 2009. CONCLUSIONS: Pharmacological treatments for 
wet-AMD are photo dynamic therapy with verteporﬁ n, pegaptanib, verteporﬁ n and 
ramibizumab, with the last one having the highest medical costs. The aging of the 
population and development of new drugs will probably increase the future economic 
impact of AMD, which remains a major health care burden.
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OBJECTIVES: To describe total costs and factors predicting cost in Germany for 
glaucoma disease states: ocular hypertension (OHT), and early (EARLY), moderate 
(MOD) and advanced (ADV) glaucoma. METHODS: A 5-year retrospective analysis 
collected health care utilization, clinical parameters, treatment(s) used and reasons for 
treatment change. Disease states deﬁ ned by the European Glaucoma Society were 
applied. Costs for health care resources were based upon the German EBM/OPS code 
for ambulatory visits/procedures, diagnosis-related groups for hospital procedures and 
the Rote Liste for medication. Factors predicting cost were identiﬁ ed using stepwise 
backward multiple linear regression, entry criterion a = 0.2. RESULTS: A total of 154 
patients (27 OHT, 43 EARLY, 35 MOD, 49 ADV) were enrolled from 15 centers 
across 5 German regions. Average age was 67 ± 11 and 57% were female. Number 
of years since diagnosis was 9.0 ± 5.7, 8.7 ± 4.6, 8.7 ± 4.1 and 13.2 ± 8.3 years for 
OHT, EARLY, MOD and ADV, respectively. Total costs, for patients with OHT, 
EARLY, MOD or ADV, were c226 ± 117, c423 ± 647, c493 ± 385, and c808 ± 877, 
respectively. Most costs were due to medication (c121 ± 99, c217 ± 150, c245 ± 161, 
c340 ± 193) and hospital interventions (c32 ± 101, c115 ± 538, c154 ± 285, c367 ± 
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811). Other costs included consultations (c54, c63, c64, c58) and examinations (c19, 
c26, c26, c26). Factors predicting high cost (R2 = 0.6426) were the number of hospital 
interventions, treatment switches, disease state changes, current disease state and issues 
with ocular burning, stinging or aching affecting daily activities. For glaucoma patients 
having 0, 1, 2 or ≥3 treatment switches this gave total costs of c273 ± 108, c320 ± 
231, c511 ± 462 and c932 ± 950, respectively. Medication costs were c177, c187, 
c268 and c368, and interventional procedure costs were c0, c50, c166 and c478, 
respectively. CONCLUSIONS: Glaucoma treatments (medication and interventional 
procedures) are the key cost drivers in management of glaucoma in Germany. Avoiding 
treatment switches, disease progression and interventional procedures should have an 
impact on the cost of glaucoma care.
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OBJECTIVES: To estimate the cost of treatment of glaucoma in Sweden and cost by 
treatment change. METHODS: Two private ophthalmologic clinics in southern 
Sweden were chosen for a retrospective chart review. Longitudinal data from patients 
older than 18 years was extracted from digitalized medical records. a glaucoma 
diagnosis (ICD-10: H40) and prescription of glaucoma treatment (ATC: S01E) were 
used as search terms to identify patients. Data on outpatient visits, glaucoma related 
pharmaceuticals and laser surgery was collected for the period 2004-01-01 to 2009-
06-30. Unit prices from ofﬁ cial sources in year 2008. Health care provider costs 
incurred during year 2008 were stratiﬁ ed according to the number of treatment 
changes. RESULTS: A total of 815 patients with pharmacological treatment were 
included in the analysis. Mean age was 77.6, 63% were female, 39% had ocular 
hypertension (OHT), 55% primary open angle glaucoma (POAG) and 6% other 
glaucoma diagnosis. Mean direct medical cost per patient during 2008 was c393. The 
cost per patient varied depending on diagnosis and number of treatment changes since 
2004. Costs for patients diagnosed with OHT, POAG and other glaucoma was c341, 
c423 and c477, respectively. Patients diagnosed with POAG ranged from c350 (no 
change in treatment) to c540 (3 or more changes). Patients with OHT ranged from 
c301 (no changes in treatment) to c613 (3 or more changes). Costs were approxi-
mately equally split between outpatient visits and drugs regardless of diagnosis or 
treatment changes. Regression analysis also revealed that costs were signiﬁ cantly 
inﬂ uenced by years since diagnosis and clinic of enrolment. CONCLUSIONS: The 
annual cost of glaucoma treatment in Sweden is estimated to c393 in 2008. Costs 
increase with number of treatment changes but also depend on diagnosis, years since 
diagnosis and clinic of enrolment. This is in line with other studies.
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OBJECTIVES: To determine the clinical and cost-effectiveness of the low friction 
ParafrictaTM products to reduce pressure ulceration on pre-existing skin breakdown 
within a hospital setting. METHODS: Patients admitted to the participating hospital 
wards who had a Waterlow score ≥15 and were unable to reposition independently, 
were offered the Parafricta products. Assessments of their level of ulceration and 
outcome were made over a 3-month period prior to the use of Parafricta products and 
then for a further three months during which Parafricta products were used. RESULTS: 
A total of 650 patient cases were assessed. Of these, 204 patient cases met the inclusion 
criteria in the three months prior to Parafricta use and 165 patient cases during 
Parafricta use. The results demonstrated that, in patients at risk of skin breakdown, 
there was a statistically signiﬁ cant reduction in the number of patients who developed 
ulceration with the use of Parafricta products (16% reduction; p = 0.0286). In addi-
tion, the number of patients who were ulcer-free on admission but who developed 
ulceration and then went on to improve or completely heal before discharge was also 
statistically signiﬁ cant (41% increase; p = 0.0065). Fewer patients admitted with 
ulceration deteriorated on the Parafricta products (21% reduction; p = 0.0012). The 
results were used to build a cost-effectiveness model and locally derived costs for 
length of stay, wound dressings and mattresses, as well as the additional cost of the 
Prafricta products were applied to determine the overall costs savings that would result 
from the reduction in ulceration on Parafricta products. The base-case model indicated 
a saving of over £63,000 per 100 incidences. CONCLUSIONS: The results of this 
evaluation support the conclusion that Parafricta products in an acute inpatient 
environment have a signiﬁ cant role to play in the avoidance of skin breakdown, and 
that they constitute an intervention that is both clinically effective and 
cost-effective.
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OBJECTIVES: The study examines the cost-effectiveness of calcipotriol 50 mcg/g plus 
betamethasone dipropionate 0.5 mg/g in combination in a new convenient gel formu-
lation for the treatment of scalp psoriasis compared to existing alternatives in Norway. 
METHODS: A decision analytic model with a time horizon of 16 weeks was devel-
oped. The perspective chosen is that of the Norwegian health care system. Responders 
to treatment were deﬁ ned as cleared or almost cleared and efﬁ cacy was derived from 
two clinical trials. Relapse rates were estimated from data in the literature. The alterna-
tive treatments were betamethasone dipropionate gel and calcipotriol gel, comparators 
in the clinical trials, matched to marketed formulations in Norway. Costs of medical 
therapy and follow-up management in scalp psoriasis in 2009 were taken from the 
Norwegian Medicines Agency and hospital price lists. The outcomes were measured 
in QALYs derived from SF-36 collected in one of the clinical trials. RESULTS: The 
overall cost for calcipotriol liniment treatment added up to 2340 NOK over 16 weeks 
and for calcipotriol/betamethasone dipropionate gel 1497 NOK and betamethasone 
dipropionate liniment 1407 NOK (1 NOK = 0.127 EUR). The treatment associated 
with the best outcome was calcipotriol/betamethasone dipropionate gel, generating a 
gain in change from baseline over 16 weeks of 0.0111 QALYs while calcipotriol gener-
ated 0.0091 QALYs and betamethasone dipropionate 0.0106 QALYs. The analysis 
showed that calcipotriol/betamethasone dipropionate gel is a dominant treatment 
compared to calcipotriol. The ICER was 180,000 NOK per QALY gained compared 
to betamethasone dipropionate. The probabilistic sensitivity analysis showed a prob-
ability of calcipotriol/betamethasone dipropionate gel being cost-effective of 82% at 
a WTP of 400,000 NOK compared to betamethasone dipropionate. CONCLUSIONS: 
The new gel formulation of calcipotriol/betamethasone dipropionate indicated for the 
treatment of scalp psoriasis is a cost-effective alternative to both calcipotriol liniment 
and to betamethasone dipropionate liniment in a Norwegian health care setting.
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OBJECTIVES: To investigate the cost-effectiveness of ranibizumab in relation to 
verteporﬁ n photodynamic therapy (PDT), pegaptanib sodium and best supportive care 
(BSC) for the treatment of Age-Related Macular Degeneration (AMD) at varying 
disease states in the Greek health care setting. METHODS: A six-state Markov model 
was constructed according to patient visual acuity in the better seeing eye. Data on 
effectiveness were derived from randomized controlled trials comparing the outcomes 
of ranibizumab 0.5 mg administered over a 2year period (8 injections in the ﬁ rst year 
of treatment, 6 in the second) versus other alternative comparators for the treatment 
of AMD patients with predominantly classic (PC) lesions and versus BSC and pegap-
tanib for those with minimally classic (MC) or occult lesions. Resource utilization 
reﬂ ected the Greek health care setting and was deﬁ ned via a panel of experts. Eco-
nomic and clinical outcomes were estimated over a 10year timeframe from the perspec-
tive of a third-party payer (social insurance fund), discounted at 3.5% per annum. 
RESULTS: the estimated mean 10-year direct treatment cost in the ranibizumab arm 
ranged from c24,844 to c32,931 with a projected beneﬁ t of 4.50–4.74 Quality 
Adjusted Life-years, depending on type of lesion. For PC lesions, the cost per QALY 
gained with ranibizumab was estimated at c10,037, c19,152 and c3,759 relative to 
PDT, BSC and pegaptanib, respectively. The corresponding ratios for patients with 
MC lesions were c28,201/QALY and c19,018/QALY for ranibizumab relative to BSC 
and pegaptanib, whereas for patients with occult lesions were estimated at c23,976/
QALY and c39,696/QALY respectively. The probability of ranibizumab being cost-
effective at the c30,000/QALY threshold was 92.6%, 83.0% and 100% (PC lesions), 
67% and 87% (MC) and 75% and 42% (occult) for the above presented ICERs. 
CONCLUSIONS: ranibizumab may be a cost-effective option for the treatment of 
AMD compared to selected alternatives in the Greek health care setting.
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OBJECTIVES: Using data from a recently published head to head clinical trial com-
paring the efﬁ cacy and safety of the ﬁ xed combination bimatoprost/timolol (BTFC, 
Ganfort®) versus ﬁ xed combination latanoprost/timolol (LTFC, Xalacom®), the 
objective was to investigate the cost-effectiveness of BTFC versus LTFC in 10 Euro-
pean countries. METHODS: A model was developed to evaluate the cost-effectiveness 
of BTFC versus LTFC taking a health care perspective including only direct health care 
costs. Efﬁ cacy data originated from a recent head to head trial of BTFC and LTFC. 
Outcomes where measured as percentage reduction in intraocular pressure (IOP) from 
baseline and percentage of patients achieving >15% and >20% reduction in IOP from 
baseline, respectively. Safety was not included in the base-case analyses as no signiﬁ cant 
